Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.

Soldevilla B, Carretero-Puche C, Gomez-Lopez G, Al-Shahrour F, Riesco MC, Gil-Calderon B, Alvarez-Vallina L, Espinosa-Olarte P, Gomez-Esteves G, Rubio-Cuesta B, Sarmentero J, La Salvia A, Garcia-Carbonero R.

Eur J Cancer. 2019 Dec;123:118-129. doi: 10.1016/j.ejca.2019.09.008. Epub 2019 Nov 1.

2.

Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas.

Capdevila J, Arqués O, Hernandez Mora JR, Matito J, Caratu G, Mancuso FM, Landolfi S, Barriuso J, Jimenez-Fonseca P, Lopez Lopez C, Garcia-Carbonero R, Hernando J, Matos I, Paolo N, Hernández-Losa J, Esteller M, Martínez-Cardús A, Tabernero J, Vivancos A, Palmer HG.

Clin Cancer Res. 2019 Oct 31. pii: clincanres.1266.2019. doi: 10.1158/1078-0432.CCR-19-1266. [Epub ahead of print]

PMID:
31672771
3.

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer.

Cardone C, Martinelli E, Troiani T, Sforza V, Avallone A, Nappi A, Montesarchio V, Andreozzi F, Biglietto M, Calabrese F, Bordonaro R, Cordio S, Bregni G, Febbraro A, Garcia-Carbonero R, Feliu J, Cervantes A, Ciardiello F.

ESMO Open. 2019 Aug 16;4(4):e000519. doi: 10.1136/esmoopen-2019-000519. eCollection 2019.

4.

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).

Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, Garcia-Carbonero R, Custodio A, Benavent M, Alonso Gordoa T, Nuñez-Valdovino B, Sanchez Canovas M, Matos I, Alonso V, Lopez C, Viudez A, Izquierdo M, Calvo-Temprano D, Grande E, Capdevila J, Jimenez-Fonseca P.

Br J Cancer. 2019 Oct;121(7):537-544. doi: 10.1038/s41416-019-0558-7. Epub 2019 Sep 3.

5.

Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.

Fernández-Martos C, Pericay C, Losa F, García-Carbonero R, Layos L, Rodríguez-Salas N, Martin-Richard M, Alonso-Orduña V, Vera R, Gallego J, Capdevila J, Salud A, Nogué M, Maurel J, Guash I, Montagut C, Lopez C, Macias I, Jain RK, Garcia-Albeniz X.

JAMA Oncol. 2019 Aug 29. doi: 10.1001/jamaoncol.2019.2294. [Epub ahead of print]

PMID:
31465088
6.

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.

Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, Barriuso J, Castaño Á, Benavent M, Alonso V, Riesco-Martínez MDC, Alonso-Gordoa T, Custodio A, Sánchez Cánovas M, Hernando Cubero J, López C, Lacasta A, Fernández Montes A, Marazuela M, Crespo G, Escudero P, Diaz JÁ, Feliciangeli E, Gallego J, Llanos M, Segura Á, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle JW, García-Carbonero R.

J Clin Oncol. 2019 Oct 1;37(28):2571-2580. doi: 10.1200/JCO.19.00980. Epub 2019 Aug 7.

7.

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Sci Rep. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z.

8.

Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.

Garcia-Carbonero R, Marquez-Rodas I, de la Cruz-Merino L, Martinez-Trufero J, Cabrera MA, Piulats JM, Capdevila J, Grande E, Martin-Algarra S, Berrocal A.

Oncologist. 2019 Oct;24(10):1375-1383. doi: 10.1634/theoncologist.2018-0718. Epub 2019 Apr 8. Review.

PMID:
30962295
9.

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.

Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Kozloff M, Simionato F, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J.

Cancer Chemother Pharmacol. 2019 May;83(5):975-991. doi: 10.1007/s00280-019-03807-4. Epub 2019 Mar 18.

PMID:
30887178
10.

Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review.

Grande E, Díaz Á, López C, Munarriz J, Reina JJ, Vera R, Bernárdez B, Aller J, Capdevila J, Garcia-Carbonero R, Jimenez Fonseca P, Trapero-Bertran M.

Ther Adv Endocrinol Metab. 2019 Feb 18;10:2042018819828217. doi: 10.1177/2042018819828217. eCollection 2019. Review.

11.

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.

Sci Rep. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. Erratum in: Sci Rep. 2019 May 17;9(1):7706.

12.

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.

Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C.

Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005.

PMID:
30689692
13.

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018).

González-Flores E, Serrano R, Sevilla I, Viúdez A, Barriuso J, Benavent M, Capdevila J, Jimenez-Fonseca P, López C, Garcia-Carbonero R.

Clin Transl Oncol. 2019 Jan;21(1):55-63. doi: 10.1007/s12094-018-1980-7. Epub 2018 Dec 7.

14.

HER2-targeted therapy: an emerging strategy in advanced colorectal cancer.

La Salvia A, Lopez-Gomez V, Garcia-Carbonero R.

Expert Opin Investig Drugs. 2019 Jan;28(1):29-38. doi: 10.1080/13543784.2019.1555583. Epub 2018 Dec 9. Review.

PMID:
30513002
15.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.

Yoshino T, Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, García-Alfonso P, Cohn AL, Van Cutsem E, Yamazaki K, Lonardi S, Muro K, Kim TW, Yamaguchi K, Grothey A, O'Connor J, Taieb J, Wijayawardana SR, Hozak RR, Nasroulah F, Tabernero J.

Ann Oncol. 2019 Jan 1;30(1):124-131. doi: 10.1093/annonc/mdy461.

16.

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.

Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Oettle H, Kozloff M, Cleverly A, Smith C, Estrem ST, Gueorguieva I, Lahn MMF, Blunt A, Benhadji KA, Tabernero J.

Br J Cancer. 2018 Nov;119(10):1208-1214. doi: 10.1038/s41416-018-0246-z. Epub 2018 Oct 15.

17.

Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours.

Barriuso J, Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, García-Carbonero R, Grande E, Jimenez-Fonseca P, Marazuela M, Rodríguez-Antona C, Aller J.

Cancer Treat Rev. 2018 Nov;70:209-222. doi: 10.1016/j.ctrv.2018.09.008. Epub 2018 Sep 26. Review.

PMID:
30292979
18.

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner B, Hofheinz RD, Maiello E, André T, Spallanzani A, Garcia-Carbonero R, Arriaga YE, Verma U, Grothey A, Kappeler C, Miriyala A, Kalmus J, Falcone A, Zaniboni A.

Oncologist. 2019 Feb;24(2):185-192. doi: 10.1634/theoncologist.2018-0072. Epub 2018 Sep 6.

PMID:
30190299
19.

Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3).

Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, Frilling A, Grossman A, Kaltsas G, Scarpa A, Welin S, Garcia-Carbonero R; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2019;108(1):54-62. doi: 10.1159/000493318. Epub 2018 Aug 28.

20.

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.

Capdevila J, Teulé A, Barriuso J, Castellano D, Lopez C, Manzano JL, Alonso V, García-Carbonero R, Dotor E, Matos I, Custodio A, Casanovas O, Salazar R; EVERLAR study investigators.

Oncologist. 2019 Jan;24(1):38-46. doi: 10.1634/theoncologist.2017-0622. Epub 2018 May 23.

PMID:
29794066
21.

The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.

Martinez-Perez J, Riesco-Martinez MC, Garcia-Carbonero R.

Expert Opin Drug Saf. 2018 Jun;17(6):643-650. doi: 10.1080/14740338.2018.1475557. Epub 2018 May 23. Review.

PMID:
29745737
22.

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set.

Grothey A, Yoshino T, Bodoky G, Ciuleanu T, Garcia-Carbonero R, García-Alfonso P, Van Cutsem E, Muro K, Mytelka DS, Li L, Lipkovich O, Hsu Y, Sashegyi A, Ferry D, Nasroulah F, Tabernero J.

ESMO Open. 2018 Apr 24;3(3):e000347. doi: 10.1136/esmoopen-2018-000347. eCollection 2018.

23.

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).

Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R.

Oncologist. 2018 Apr;23(4):422-432. doi: 10.1634/theoncologist.2017-0364. Epub 2018 Jan 12.

24.

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.

Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R.

Endocr Relat Cancer. 2018 Mar;25(3):309-322. doi: 10.1530/ERC-17-0455. Epub 2018 Jan 12.

25.

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.

Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC.

Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14.

26.

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.

Tabernero J, Hozak RR, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Prausová J, Muro K, Siegel RW, Konrad RJ, Ouyang H, Melemed SA, Ferry D, Nasroulah F, Van Cutsem E.

Ann Oncol. 2018 Mar 1;29(3):602-609. doi: 10.1093/annonc/mdx767.

27.

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial.

Van Cutsem E, Falcone A, Garcia-Carbonero R, Komatsu Y, Pastorino A, Peeters M, Shimada Y, Yamazaki K, Yoshino T, Zaniboni A, Amellal N, Kanehisa A, Winkler R, Makris L, Mayer RJ, Ohtsu A, Tabernero J.

ESMO Open. 2017 Nov 23;2(5):e000261. doi: 10.1136/esmoopen-2017-000261. eCollection 2017.

28.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H.

Oncologist. 2017 Oct;22(10):1281. doi: 10.1634/theoncologist.2016-0133erratum. No abstract available.

29.

Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.

Riesco-Martinez MC, Sanchez-Torre A, Garcia-Carbonero R.

Expert Opin Investig Drugs. 2017 Nov;26(11):1295-1305. doi: 10.1080/13543784.2017.1385762. Epub 2017 Oct 6. Review.

PMID:
28965421
30.

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, Van Cutsem E, Guan X, Boedigheimer M, Ang A, Twomey B, Bach BA, Jung AS, Bardelli A.

Ann Oncol. 2018 Jan 1;29(1):119-126. doi: 10.1093/annonc/mdx504.

31.

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K.

J Immunother Cancer. 2017 Sep 19;5(1):71. doi: 10.1186/s40425-017-0277-7.

32.

Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Grande E, Capdevila J, López C, Teule A, Garcia-Carbonero R; Spanish Neuroendocrine Tumor Group (GETNE).

Curr Oncol Rep. 2017 Sep 18;19(11):72. doi: 10.1007/s11912-017-0633-2. Review.

PMID:
28920153
33.

Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.

Cohn AL, Yoshino T, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O'Brien LM, Gao L, Yang L, Ferry D, Nasroulah F, Tabernero J.

Cancer Chemother Pharmacol. 2017 Sep;80(3):599-608. doi: 10.1007/s00280-017-3380-z. Epub 2017 Jul 25.

34.

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R.

Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16.

35.

Prognostic relevance of Src activation in stage II-III colon cancer.

Martínez-Pérez J, Lopez-Calderero I, Saez C, Benavent M, Limon ML, Gonzalez-Exposito R, Soldevilla B, Riesco-Martínez MC, Salamanca J, Carnero A, Garcia-Carbonero R.

Hum Pathol. 2017 Sep;67:119-125. doi: 10.1016/j.humpath.2017.05.025. Epub 2017 Jun 7.

PMID:
28601656
36.

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.

Yoshino T, Obermannová R, Bodoky G, Garcia-Carbonero R, Ciuleanu T, Portnoy DC, Kim TW, Hsu Y, Ferry D, Nasroulah F, Tabernero J.

Eur J Cancer. 2017 Jun;78:61-69. doi: 10.1016/j.ejca.2017.03.007. Epub 2017 Apr 13.

37.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy.

Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, O Connor J, Eriksson B, Sorbye H, Kulke M, Chen J, Falkerby J, Costa F, de Herder W, Lombard-Bohas C, Pavel M; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):281-294. doi: 10.1159/000473892. Epub 2017 Apr 5. No abstract available.

PMID:
28380493
38.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents.

Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J, Sorbye H, Garcia-Carbonero R; Antibes Consensus Conference Participants; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):266-280. doi: 10.1159/000471880. Epub 2017 Mar 29. No abstract available.

PMID:
28351033
39.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H.

Oncologist. 2017 Apr;22(4):375-e30. doi: 10.1634/theoncologist.2016-0133. Epub 2017 Mar 8. Erratum in: Oncologist. 2017 Oct;22(10 ):1281.

40.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors.

Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, Hörsch D, Tiensuu Janson E, Kianmanesh R, Kos-Kudla B, Pavel M, Rinke A, Falconi M, de Herder WW; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):245-254. doi: 10.1159/000461583. Epub 2017 Mar 2. No abstract available.

41.

Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.

Salvador J, Aparicio J, Baron FJ, García-Campelo R, Garcia-Carbonero R, Lianes P, Llombart A, Isla D, Piera JM, Muñoz M, Puente J, Rivera F, Rodríguez CA, Virizuela JA, Martín M, Garrido P.

Clin Transl Oncol. 2017 Apr;19(4):525. doi: 10.1007/s12094-017-1628-z. No abstract available.

42.

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.

Michael M, Garcia-Carbonero R, Weber MM, Lombard-Bohas C, Toumpanakis C, Hicks RJ.

Oncologist. 2017 Mar;22(3):272-285. doi: 10.1634/theoncologist.2016-0305. Epub 2017 Feb 20. Review.

43.

Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas.

Lamarca A, Walter T, Pavel M, Borbath I, Freis P, Nuñez B, Childs A, McNamara MG, Hubner RA, Garcia-Carbonero R, Meyer T, Valle JW, Barriuso J.

J Natl Cancer Inst. 2017 Jan 27;109(5). doi: 10.1093/jnci/djw277. Print 2017 Jan.

PMID:
28130474
44.

Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.

Perez M, Lucena-Cacace A, Marín-Gómez LM, Padillo-Ruiz J, Robles-Frias MJ, Saez C, Garcia-Carbonero R, Carnero A.

Oncotarget. 2016 Nov 22;7(47):78219. doi: 10.18632/oncotarget.13482. No abstract available.

45.

Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.

Sevilla I, Segura Á, Capdevila J, López C, García-Carbonero R, Grande E; GETNE (Spanish Group of NeuroEndocrine Tumors).

BMC Cancer. 2016 Nov 7;16(1):858.

46.

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.

Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J.

Ann Oncol. 2016 Nov;27(11):2082-2090. Epub 2016 Aug 29.

47.

Translational research in neuroendocrine tumors: pitfalls and opportunities.

Capdevila J, Casanovas O, Salazar R, Castellano D, Segura A, Fuster P, Aller J, García-Carbonero R, Jimenez-Fonseca P, Grande E, Castaño JP.

Oncogene. 2017 Apr 6;36(14):1899-1907. doi: 10.1038/onc.2016.316. Epub 2016 Sep 19. Review.

PMID:
27641330
48.

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.

Salvador J, Aparicio J, Baron FJ, Garcia-Campelo R, Garcia-Carbonero R, Lianes P, Llombart A, Isla D, Piera JM, Munoz M, Puente J, Rivera F, Rodriguez CA, Virizuela JA, Martin M, Garrido P.

Clin Transl Oncol. 2017 Mar;19(3):341-356. doi: 10.1007/s12094-016-1535-8. Epub 2016 Aug 25. Erratum in: Clin Transl Oncol. 2017 Apr;19(4):525. multiple author names corrected.

49.

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.

Longo-Muñoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, Gil-Calle S, Mizuguchi H, Carrato-Mena A, Limón ML, Garcia-Carbonero R.

Clin Transl Oncol. 2017 Feb;19(2):227-235. doi: 10.1007/s12094-016-1528-7. Epub 2016 Jul 21.

50.

Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case.

Manneh R, Castellano D, Caso O, Loinaz C, Jiménez J, Estenoz J, Calatayud M, Sepúlveda JM, García-Carbonero R.

Case Rep Oncol. 2016 Apr 27;9(1):255-61. doi: 10.1159/000445940. eCollection 2016 Jan-Apr.

Supplemental Content

Loading ...
Support Center